Table 2.

Brain regions with significant flow–metabolism dissociation during levodopa treatment

	Coordinates^a			Zmax	CMR^b		CBF^c
	x	y	z	Zmax	LD (OFF)	LD (ON)	LD (OFF)	LD (ON)
Putamen/GP	−30	−8	2	4.82****	2.01 (0.05)	1.89 (0.05)^†††	1.70 (0.02)	1.80 (0.04)^†††
	32	−4	−2	3.63**	2.05 (0.05)	1.95 (0.05)^†	1.78 (0.03)	1.85 (0.04)^†
Thalamus	12	−22	0	3.05*	1.88 (0.04)	1.80 (0.03)^†	1.81 (0.03)	1.86 (0.03)^†
Subthalamic nucleus	10	−10	−4	2.88*	1.49 (0.04)	1.44 (0.03)^††	1.62 (0.03)	1.67 (0.03)^†
Dorsal pons	6	−34	−32	4.85***	1.36 (0.04)	1.32 (0.03)^†	1.61 (0.03)	1.74 (0.04)^†††

↵^aMontreal Neurological Institute (MNI) standard space.
↵^bGlobally normalized CMR for glucose (mean ± SE) in each VOI (see Materials and Methods).
↵^cGlobally normalized CBF (mean ± SE) in each VOI (see Materials and Methods).
Significant flow–metabolism dissociation (SPM interaction analysis): *p < 0.001, uncorrected; **p < 0.05, extent corrected; ***p < 0.005, ****p < 0.001, cluster corrected with voxel-level familywise error correction (p < 0.05).
Significant ON–OFF differences (paired t test): ^†p < 0.05; ^††p < 0.01; ^†††p < 0.001.